You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百济神州(06160.HK)发布替雷利珠单抗临床数据
阿思达克 11-26 08:22

百济神州(06160.HK)公布替雷利珠单抗临床数据。截至数据截点,8例患者仍在接受替雷利珠单抗治疗,包括4例G/GEJ腺癌患者和4例ESCC患者。替雷利珠单抗联合化疗用於治疗胃/胃食管结合部腺癌患者以及食管鳞状细胞癌患者的一项2期临床试验的初步数据。

公司肿瘤免疫学首席医学官贲勇表示:替雷利珠单抗与化疗的联合治疗在这项针对G/GEJ腺癌和ESCC患者的试验中展示了持久的缓解,并且总体耐受。胃癌和食管癌位居全球最常见癌种之列,有着高度未满足的治疗需求,特别是在中国需求更加突出。公司很欣慰能够在这些癌症以及其他亚洲地区高发癌症中继续开展替雷利珠单抗的後期开发。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account